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The aim of this retrospective study of 56 patients with minor salivary gland tumours (MSGTs) of the upper aerodigestive tract is
to present demographic features, distribution of tumours as well as methods and results of treatment performed in our institution
over a 10-year period. Of 221 patients with salivary gland tumours, 56 patients with MSGT were selected. There were 36 female
and 20 male patients aged from 8 to 81 years. Male-to-female ratio was 1:2 in the group of benign MSGT and 1:1.7 in the group
of malignant tumours. The palate was the most frequent site of MSGT (45.6%), followed by buccal mucosa (19.3%). Of all MSGTs
63.2% were malignant, and 36.8% were benign. Adenoid cystic carcinoma was the most common neoplasm (31.6%), followed by
pleomorphic adenoma (29.8%). Surgery was the method of choice in the treatment of patients with MSGT. Postoperative defects
were reconstructed by prosthetic obturators, local ﬂaps, and free radial forearm ﬂap. Relative survival for patients with malignant
MSGT was 88% at three years and 71.5% at ﬁve years. MSGTs are more frequent in females and predominantly aﬀect the palate.
Malignant MSGTs are more common than benign.
1.Introduction
Primary tumours arising from minor salivary glands, dis-
tributed in the palate, buccal mucosa, tongue, lips, paranasal
sinuses, pharynx, and larynx, are relatively uncommon. Mi-
nor salivary gland tumours (MSGTs) represent 9–25% of all
salivary gland tumours [1] as well as 2-3% of all head and
neck tumours [2] with a femalepreponderance [1–3].Unlike
major salivary gland neoplasms, the majority of MSGTs are
malignant. The two most common malignant MSGTs are
mucoepidermoid carcinoma and adenoid cystic carcinoma
[3, 4]. Pleomorphic adenoma is the most frequent benign
tumour arising from minor salivary glands. The palate, espe-
cially the junction between the soft and hard palate, is the
most typical location of MSGTs [5].
Due to complex histopathology of MSGTs, diagnostics
and treatment planning are challenging. Histological classiﬁ-
cation of salivary gland tumours is still changing (according
to the latest WHO modiﬁcation in 2005) [6].
The aim of this retrospective study with MSGTs of the
upper aerodigestive tract is to present methods and results
of treatment performed in our institution over a 10-year
period.
2.MaterialandMethods
The records of 221 patients with salivary gland tumours were
retrospectively reviewed, and the group of 56 patients with
MSGTs, treated over a 10 year period, was selected.
Patients’ demographic data, comorbidities, symptoms,
tumour locations, diagnostic methods, histological diagno-
sis, and therapeutic methods, including reconstructive pro-
cedures, were analyzed. Radicality of surgery was assessed.
Oncologic outcomes (recurrence and ﬁve year survival) were
also analysed. Data was collected using Excel 2007 Microsoft
Oﬃce.
3. Results
Between 2000 and 2009, 56 patients with 57 MSGTs were
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Figure 1: Adenoid cystic carcinoma of the hard palate.
years. The mean age of the patients with benign MSGTs was
lower (48.3 years) than of those with malignant MSGTs (51.3
years).
There were 36 females and 20 males with the male-to-
female ratio of 1:2 in the group of benign MSGTs and 1:1.7
in the group of malignant tumours. The time either from
occurrence of the ﬁrst symptoms or from initial diagnosis
to surgery, ranged from 2 months to 30 years (3 years and 2
monthsonaverage).PatientswithbenignMSGTsdelayedthe
treatment for 4 years, whereas those with malignant MSGTs
for 2 years and 8 months on average. The most common
comorbidities in this study comprised of hypertension (13
cases), struma nodosa (5 cases), gastric ulcer (4), cholecys-
tolithiasis (4) and less frequently chronic gastritis, diabetes,
gout,andhypothyroidism.Tobaccosmokingwasdeclaredby
13 (23.2%) patients.
Intwocases,developmentofothersalivaryglandtumour
preceded MSGTs. In the ﬁrst patient, basal cell adenoma of
the buccal mucosa followed adenoid cystic carcinoma of the
maxilla. In the second case, acinic cell carcinoma of the hard
palate followed pleomorphic adenoma of the parotid gland.
The majority of patients with MSGTs were asymp-
tomatic, especially in the group of benign tumours, where
pain was presented only in 4 cases. Patients with malignant
MSGTs complained of pain (5 cases), bleeding ulceration (11
cases), and loose teeth. The palate was the most frequent site
of MSGTs—26 cases (45.6%), followed by buccal mucosa
and maxilla (Figures 1, 2,a n d3). In addition, the palate
was the most common site for both benign (53.8%) and
malignant (46.2%) MSGTs. Majority of buccal mucosa
tumours were benign (63.6%); however, MSGTs of maxilla,
tongue, lips, ﬂoor of the mouth and retromolar region were
all malignant. The location of benign and malignant MSGTs
is depicted in Table 1.
Initial histologic diagnosis of MSGTs was obtained with
open biopsy in 39 cases, ﬁne needle aspiration cytology
(FNAC) in 19 patients, and intraoperative frozen section
analysis in 8. The results consistent with the ﬁnal diagnosis
were obtained in 7 FNAC examinations only, including 2
cases of malignant MSGTs. In two out of 14 open biopsies
of benign MSGTs and in one out of 25 open biopsies of
malignant tumours, the results were opposite to the ﬁnal
diagnosis. The results obtained by frozen section analysis
showed negative resection margins in 8 cases. In 4 cases,
Figure 2: Pleomorphic adenoma of the junction between the soft
and hard palate.
Figure 3: Adenoid cystic carcinoma of the left maxilla.
Table 1: Tumour location.
Type of
tumour Location Number of
cases
Benign
Palate 14
Hard palate 10
Soft palate 1
Hard + soft 3
Buccal mucosa 7
Malignant
Palate 12
Hard palate 9
Soft palate 3
Maxilla 11
Buccal mucosa 4
Labial mucosa 3
Upper lip 2
Lower lip 1
Tongue 2
Floor of the mouth 2
Retromolar region 2
Total: 57
tumours∗
∗In one patients two MSGTs were diagnosed.
preliminary histologic diagnosis was consistent with ﬁnal
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Table 2: Histological type of minor salivary gland tumours.
Type of tumour Number
Benign 21 (36.8%)
Pleomorphic adenoma 17
Myoepithelioma 1
Pleomorphic adenoma and myoepithelioma 1
Monomorphic adenoma 1
Basal cell adenoma 1
Malignant 36 (63.2%)
Adenoid cystic carcinoma 18
Mucoepidermoid carcinoma 8
Adenocarcinoma 4
Acinic cell carcinoma 3
Papillary cystadenocarcinoma 1
Carcinoma ex pleomorphic adenoma 1
Undiﬀerentiated carcinoma 1
Total: 57 tumours∗
∗In one patients two MSGTs were diagnosed.
Histologic examination revealed 36 malignant MSGTs
(63.2%) and 21 benign MSGTs (36.8%). Adenoid cystic car-
cinoma was the most common neoplasm: 18 (31.6%), fol-
lowed by pleomorphic adenoma: 17 (29.8%). Of all malig-
nant MSGT, mucoepidermoid carcinoma was the second
most common neoplasm (14%).
Isolated cases of myoepithelioma, monomorphic ade-
noma,basalcelladenoma,andahybridtumourwithfeatures
of both pleomorphic adenoma, and myoepithelioma were
found in the benign group. Histologic types of MSGTs are
presented in Table 2.
Stage of presentation was established in 34 cases out of
36 patients with malignant MSGTs. More than half of the
patients presented in advanced stage disease (stage IV: 14,
stage III: 5, stage II: 10, and stage I: 5 patients).
Surgery was the method of choice in the treatment of
patientswithMSGTs.Additionaltreatmentsinthemalignant
MSGTs group included neoadjuvant chemotherapy (1 case)
and adjuvant radiotherapy (14 cases). Surgical treatment
comprised of maxillectomy (various levels, including eth-
moidectomy and exenteration of the orbit) in 18 cases and
tumour excision in 18 patients, including resection of under-
lying bone in 7 cases. Concomitant neck dissection was per-
formed in 9 patients. In this group, three patients required
radical neck dissection, one selective neck dissection, and in
5 cases limited lymphadenectomy was performed.
Postoperative defects were reconstructed by prosthetic
obturators in 22 patients and local ﬂaps in 10 cases (Figures
4(a)–4(e)). Additionally the cervical skin ﬂap and buccal fat
pad ﬂap were used. Only in one case in this group, the defect
w a sl e f tt og r a n u l a t e .D e l a y e dr e c o n s t r u c t i o nw a sp e r f o r m e d
in 4 cases using palatal ﬂaps, tongue ﬂap, and free radial
forearm ﬂap (Figures 5(a)–5(d)).
Patients with benign MSGTs required tumour excision
in 15 cases, including bone resection in 7 cases, partial
maxillectomy in 3 patients and tumour enucleation in 3. In
this group, either simple wound closure or local ﬂaps were
used as well as prosthetic obturators.
Radical tumour excision was conﬁrmed in 19 patients
with malignant MSGTs and in 20 patients with benign
neoplasms. Patients with positive margins had either wider
resectionorradiotherapyinmalignanttumours,especiallyin
cases where extension of surgical procedure was not possible.
No recurrences were noted in patients with benign MSGTs.
Nine patients with malignant tumours (8 adenoid cystic car-
cinoma and 1 adenocarcinoma) developed local recurrence
which was observed 2 months to 11 years and 10 months
(3 years and 11 months on average) following the primary
surgicaltreatment.Secondaryneckdissectionwasperformed
in 10 patients with clinically positive lymphadenopathy.
Cervicalmetastases(levelsIB,II,andIII)wereconﬁrmedin6
cases (16.2%) and occurred on average 11 months following
the primary surgical procedure.
Three patients (8.3%) with adenoid cystic carcinoma
developed distant metastases in lungs, liver, and bones, 2 to
over 5 years following surgery, with a median time of 3 years
and 6 months.
Relative survival of our patients with malignant MSGTs
was 88% (25 cases) at three years and 71.5% (14 cases) at ﬁve
years.
4. Discussion
This retrospective analysis concerned patients from the
southern Poland, treated in the University Department of
Cranio-Maxillofacial Surgery. The present study revealed
thatmalignantMSGTsoccurredintheolderpopulationthan
benign tumours (3 years on average). This was also reported
by others [1, 2].4 Gastroenterology Research and Practice
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Figure 4: (a) Pleomorphic adenoma of the junction between the soft and hard palates in a 60-years-old female patient. (b) CT horizontal
scan of the patient. (c) Prosthetic obturator. (d) Surgical specimen of resected pleomorphic adenoma. (e) Postoperative defect.
Review of the literature shows a female predilection
among the MSGTs patients (male-to-female ratio ranging
from 1:1.02 to 1:2) [1, 4]. Higher proportion of females
was also found in our study (ratio of 1:1.8 for all MSGTs).
Reported tendency of female predominance characteristic
for benign MSGTs [7, 8] was also conﬁrmed in the present
series with a male-to-female ratio of 1:2. In patients with
malignant MSGTs the ratio was 1:1.7.
Relatively slow and almost asymptomatic growth of
MSGTs might not be noticed by a patient. Fortunately, these
tumours are often found during routine dental examination
[5].
Concomitant diseases of the digestive tract, such as
gastric ulcer, chronic gastritis, and cholecystolithiasis were
diagnosed in 10 (17.8%) patients in this series. However, we
have not found studies indicating relation between diseases
of the digestive tract and occurrence of MSGTs.
Tobacco smoking, irradiation, and history of prior neo-
plasms were mentioned in some studies [5, 9]a sp o t e n t i a l
risk factors, although the causes of MSGTs are largely un-
known. In the present study, 23.2% of patients smoked
cigarettes. As far as prior neoplasms are concerned, two pa-
tients in our series developed two histologically diﬀerent and
independent salivary gland tumours.
According to other reports [1, 3, 8, 10], the palate was the
most commonly aﬀected site, and this was also seen in our
study. In this location we found 45.6% of all MSGTs with
predominance for benign tumours (53.8%). Moore et al . [5]
suggests that MSGTs usually occurred at the junction of the
hard and soft palates due to concentration of salivary glands
in this region. However, the distribution of MSGTs found
in the present study is diﬀerent as the hard palate was the
most common site in 47.6% of benign and 25% of malignant
tumours.
Other anatomical sites of involvement diﬀer in various
studies. Pires et al. [3], Buchner et al. [10], and Yih et al.
[4] have indicated the lips, whereas Venkata [7] indicated
the alveolar mucosa as the second most common site. In
the present study, the palate was followed by the buccal
mucosa.
As in our study, review of the literature [10, 11] revealed
that MSGTs aﬀecting the retromolar region as well as the
ﬂoor of the mouth were malignant. It is believed that
malignant MSGTs predominate even up to 76% over benign
tumours [5, 7, 8]. Greater proportion, 63.2% of malignant
tumours, was also found in our series. On the other hand,
theresultsreportedinotherstudies[1,3,4,10]showedlower
incidence of malignant MSGTs.Gastroenterology Research and Practice 5
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Figure 5: (a) Postoperative defect after partial maxillectomy due to low-grade mucoepidermoid carcinoma of the hard palate in 28-year-old
female patient. (b) Radial forearm free ﬂap designed. (c) Radial forearm free ﬂap prepared for palatal reconstruction. (d) Result after 8 years
following reconstruction of the palate by radial forearm free ﬂap.
In this study, adenoid cystic carcinoma was the most
common pathological type of MSGTs (31.6%) followed by
pleomorphic adenoma (29.8%), which was also a predomi-
nant benign MSGTs. Our ﬁndings were consistent with other
series [1, 5, 10] as far as the frequency of pleomorphic
adenoma was concerned but according to other reports [4,
10, 12], mucoepidermoid carcinoma was the most common
malignant MSGTs. Studies concerning west European popu-
lation[13–15]reportedadenoidcysticcarcinomaasthemost
common malignancy.
FNAC is recommended in the preoperative diagnosis of
MSGTs, with 96% accuracy. Open biopsy of these tumours
is controversial due to potential tumour seeding [5, 9, 16].
Frozen section analysis might lead to false-positive (1.1%) or
false-negative (2.6%) rates [9]. In the present study, accuracy
of these diagnostic tools was low.
In patients with MSGTs, computed tomography (CT)
is a basic diagnostic examination in evaluation of bone
destruction and inﬁltration of surrounding tissues. Espe-
ciallyextensionintoparanasalsinuses,nasalcavity,orbit,and
pterygopalatine and infratemporal fossa can be appreciated.
Detailed assessment of soft tissues involvement might be
obtained by MRI imaging [5, 9].
The management of MSGTs remains primarily surgical
including wide excision of malignant neoplasms and enu-
cleation of encapsulated benign tumours. However, benign
MSGTsofthepalate,mainlypleomorphic adenomas,require
excision with adequate soft tissue margin as well as removal,
sometimes resection, of the underlying bone [5, 9].
Due to the low rate of cervical metastases in MSGT,
elective neck dissections are not recommended [17, 18]. This
rule was followed in the management of our patients.
Evaluation of postoperative quality of life of the patients
withMSGTsdependsonthemethodofreconstruction,espe-
cially in cases with palatal defects. Recently, primary closure
ofablativedefectsbypalatal,buccalandtongueﬂaps,tempo-
ralis myofascial ﬂap, vascularised free ﬂaps has been recom-
mended [5, 19, 20]. Still used prosthetic obturators might be
a reason for oronasal reﬂux, but they also enable direct visual
control of the operated site, which is important in patients
with malignant MSGTs. In available studies [9, 21, 22], ﬁve-
yearrelativesurvivalofthepatientswithMSGTsrangedfrom
50% to 89%, which was consistent with our ﬁndings.
5. Conclusions
(1) relatively rare MSGTs are more frequent in females
and predominantly aﬀect the palate;
(2) malignant MSGTs are more common than benign;
(3) adenoid cystic carcinoma and pleomorphic adenoma
are the most common MSGTs.
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